Quasi-randomized study demonstrates the value of Dario's
integrated approach to provide one solution for members to manage
diabetes, pre-diabetes, blood pressure, weight and taking a
GLP-1
NEW
YORK, April 25, 2024 /PRNewswire/ -- DarioHealth
Corp. (Nasdaq: DRIO) ("Dario" or the "Company"), a leader in the
global digital health market, announced today new research
published in the leading peer-reviewed journal for digital health
and medicine, Journal of Internet Medicine (JMIR)
demonstrating a clinically significant reduction in blood glucose
levels for members using Dario to manage weight alongside
diabetes.
More than 80% of people living with Type 2 diabetes are
overweight and the two conditions are closely linked to the same
underlying unhealthy behaviors. Dario's cardiometabolic solution
helps people manage related cardiometabolic health needs, including
diabetes, pre-diabetes, blood pressure, weight and support for
people taking a GLP-1, with a single integrated and highly
personalized experience. Dario's solution is designed to help
people adopt the healthier behaviors required to support improved
clinical outcomes, which includes self-health management behaviors
such as monitoring weight and blood glucose.
This new retrospective, quasi-randomized study examined the data
from 1,932 Dario members over the course of a year. Fifty percent
of the members that regularly used Dario's weight monitoring
feature were propensity score matched with 50% of the members who
did not use the weight monitoring feature based on demographic and
clinical characteristics.
Over a six-month period, members using a digital weight
monitoring feature experienced a significant reduction in blood
glucose levels and BMI, unlike the matched control group that never
used weight monitoring. Eighty-five percent of individuals in the
weight monitoring group achieved a reduction in blood glucose
levels below the estimated A1c threshold of 9.0 in their last month
of measurement compared to 76% of the individuals in the group
using Dario to manage diabetes alone. Weight variability was
positively associated with blood glucose levels while BMI lagged by
one month was not associated with blood glucose levels. These
comprehensive findings support the broader use of digital
self-monitoring tools in diabetes management, emphasizing their
role in enhancing patient outcomes through empowerment and active
participation.
"The reality for so many people living with Type 2 diabetes is
that addressing weight is a critical factor in realizing meaningful
clinical improvements. We set out to more clearly evaluate our
intensive multidisciplinary approach showing how giving people one
solution can lead to better diabetes outcomes and are thrilled to
see the data demonstrates real clinical improvements from
addressing these two conditions in one solution," said Yifat
Hershcovitz, PhD., Vice President of Clinical and Scientific
Affairs at Dario.
"Type 2 diabetes and obesity share the same web of underlying
health behaviors, and yet we often ask people to engage in multiple
solutions to address these conditions separately. It adds undue
burden to the behavior change process and can impede engagement on
one or both conditions, which ultimately hurts outcomes. The
results of this study show a clear benefit to having a single
approach, and we are excited to continue adding evidence of the
need for more integrated chronic condition solutions like Dario,"
said Omar Manejwala, M.D., Chief
Medical Officer.
The research was conducted in partnership with Integrative Pain
Laboratory, the School of Public Health at the University of Haifa.
You can access the full study here.
About DarioHealth Corp.
DarioHealth Corp. (Nasdaq: DRIO) is a leading digital health
company revolutionizing how people with chronic conditions manage
their health through a user-centric, multi-chronic condition
digital therapeutics platform. Dario's platform and suite of
solutions deliver personalized and dynamic interventions driven by
data analytics and one-on-one coaching for diabetes, hypertension,
weight management, musculoskeletal pain and behavioral
health.
Dario's user-centric platform offers people continuous and
customized care for their health, disrupting the traditional
episodic approach to healthcare. This approach empowers people to
holistically adapt their lifestyles for sustainable behavior
change, driving exceptional user satisfaction, retention and
results and making the right thing to do the easy thing to do.
Dario provides its highly user-rated solutions globally to
health plans and other payers, self-insured employers, providers of
care and consumers. To learn more about Dario and its digital
health solutions, or for more information, visit
http://dariohealth.com.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and
partners of DarioHealth Corp. related thereto contain or may
contain forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Statements that
are not statements of historical fact may be deemed to be
forward-looking statements. For example, the Company is using
forward-looking statements in this press release when it discusses
the broader use of digital self-monitoring tools in diabetes
management and its plan to continue adding evidence of the need for
more integrated chronic condition solutions. Without limiting the
generality of the foregoing, words such as "plan," "project,"
"potential," "seek," "may," "will," "expect," "believe,"
"anticipate," "intend," "could," "estimate" or "continue" are
intended to identify forward-looking statements. Readers are
cautioned that certain important factors may affect the Company's
actual results and could cause such results to differ materially
from any forward-looking statements that may be made in this news
release. Factors that may affect the Company's results include, but
are not limited to, regulatory approvals, product demand, market
acceptance, impact of competitive products and prices, product
development, commercialization or technological difficulties, the
success or failure of negotiations and trade, legal, social and
economic risks, and the risks associated with the adequacy of
existing cash resources. Additional factors that could cause or
contribute to differences between the Company's actual results and
forward-looking statements include, but are not limited to, those
risks discussed in the Company's filings with the U.S. Securities
and Exchange Commission. Readers are cautioned that actual results
(including, without limitation, the timing for and results of the
Company's commercial and regulatory plans for Dario™ as described
herein) may differ significantly from those set forth in the
forward-looking statements. The Company undertakes no obligation to
publicly update any forward-looking statements, whether as a result
of new information, future events or otherwise, except as required
by applicable law.
DarioHealth Corporate Contact
Mary Mooney
VP Marketing
+1-312-593-4280
DarioHealth Investor Relations Contact
Kat Parella
Investor Relations Manager
kat@dariohealth.com
+315-378-6922
Media Contact
Scott Stachowiak
Scott.Stachowiak@russopartnersllc.com
+1-646-942-5630
Logo -
https://mma.prnewswire.com/media/1920436/DarioHealth_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/dario-publishes-new-peer-reviewed-study-that-deepens-the-body-of-evidence-that-managing-cardiometabolic-conditions-in-one-integrated-platform-improves-clinical-outcomes-302127431.html
SOURCE DarioHealth Corp.
